Home Clinical Topics FDA approves Kalydeco for rare form of cystic fibrosis

FDA approves Kalydeco for rare form of cystic fibrosis

The U.S. Food and Drug Administration has approved Kalydeco (ivacaftor) for the treatment of a rare form of cystic fibrosis in patients ages 6 years and older who have the specific G551D mutation in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here